Search for a trial

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

This study has been transitioned to CTIS with ID 2022-500785-10-00 check the CTIS register for the current data. 1) To compare pembrolizumab plus enzalutamide versus placebo plus enzalutamide with respect to overall survival (OS)2) To compare…

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

To compare pembrolizumab plus docetaxel plus prednisone to placebo plus docetaxel plus prednisone with respect to overall survival (OS)

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

This study has been transitioned to CTIS with ID 2024-511252-41-00 check the CTIS register for the current data. The aim of the current study is to extend the time to develop new disease progression in prostate cancer patients with recurrent disease…

Magnetic Resonance Direct Thrombus Imaging for diagnostic management of suspected pelvic vein thrombosis during pregnancy -

Zie protocol, hoofdstuk 3 (Objectives)

A PHASE III, RANDOMISED CONTROLLED TRIAL ASSESSING THE VALUE OF INDOCYANINE GREEN IN THE LEAKAGE RATE OF COLORECTAL ANASTOMOSES

Primary Objective: To compare the difference in clinically relevant AL after 90 days between perfusion assessment with ICG and standard surgery in colorectal anastomoses.Secondary Objective(s): 1. Change in surgical plan will be assessed within each…

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

1) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to radiographic progression-free…

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

This study has been transitioned to CTIS with ID 2023-508101-24-00 check the CTIS register for the current data. The primary objective of the first randomized question (R1) open for allLBL patients (pts) of the core study cohort, is to evaluate…

An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma.

This study has been transitioned to CTIS with ID 2024-512222-28-00 check the CTIS register for the current data. Overall program:The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving the staging…